Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer

ConclusionsTreatment of mPC with ADT is correlated with neurocognitive deficits in several cognitive domains. Language skills and processing speed were most frequently impaired. However, a consistent pattern of cognitive impairment was not identified. Neurocognitive deficits should be considered in phase III and IV trials.Trial registrationThe study was registered in the German Clinical Trials Registry (DRKS00017727).
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research